162 related articles for article (PubMed ID: 25088191)
1. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.
Semple G; Lehmann J; Wong A; Ren A; Bruce M; Shin YJ; Sage CR; Morgan M; Chen WC; Sebring K; Chu ZL; Leonard JN; Al-Shamma H; Grottick AJ; Du F; Liang Y; Demarest K; Jones RM
Bioorg Med Chem Lett; 2012 Feb; 22(4):1750-5. PubMed ID: 22264481
[TBL] [Abstract][Full Text] [Related]
4. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.
Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Oda K; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
Bioorg Med Chem Lett; 2016 Aug; 26(15):3441-6. PubMed ID: 27390068
[TBL] [Abstract][Full Text] [Related]
6. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
7. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119.
Li G; Meng B; Yuan B; Huan Y; Zhou T; Jiang Q; Lei L; Sheng L; Wang W; Gong N; Lu Y; Ma C; Li Y; Shen Z; Huang H
Eur J Med Chem; 2020 Feb; 188():112017. PubMed ID: 31926470
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
[TBL] [Abstract][Full Text] [Related]
12. 2,5-Disubstituted pyridines as potent GPR119 agonists.
Wu Y; Kuntz JD; Carpenter AJ; Fang J; Sauls HR; Gomez DJ; Ammala C; Xu Y; Hart S; Tadepalli S
Bioorg Med Chem Lett; 2010 Apr; 20(8):2577-81. PubMed ID: 20227877
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
Ye XY; Morales CL; Wang Y; Rossi KA; Malmstrom SE; Abousleiman M; Sereda L; Apedo A; Robl JA; Miller KJ; Krupinski J; Wacker DA
Bioorg Med Chem Lett; 2014 Jun; 24(11):2539-45. PubMed ID: 24755425
[TBL] [Abstract][Full Text] [Related]
16. Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.
Matsuda D; Kobashi Y; Mikami A; Kawamura M; Shiozawa F; Kawabe K; Hamada M; Nishimoto S; Kimura K; Miyoshi M; Takayama N; Kakinuma H; Ohtake N
Bioorg Med Chem; 2017 Aug; 25(16):4339-4354. PubMed ID: 28662959
[TBL] [Abstract][Full Text] [Related]
17. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
19. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
[TBL] [Abstract][Full Text] [Related]
20. Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists.
Azimioara M; Alper P; Cow C; Mutnick D; Nikulin V; Lelais G; Mecom J; McNeill M; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessl T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 Dec; 24(23):5478-83. PubMed ID: 25455488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
